The Effect of a Synbiotic on Intestinal Barrier Function and Microbiota Modulation in Middle-aged to Elderly Individuals With Excessive Body Weight

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age50-70
SponsorChr Hansen - part of Novonesis

About this trial

The study is a single-center, randomized, double-blind, placebo-controlled study in middle-aged to elderly adults with excessive body weight. The study includes an 8-week intervention period followed by a 2-week follow-up period. The study will evaluate the effect of a synbiotic consisting of two probiotic strains and a prebiotic.

The aim is to investigate the effect of the synbiotic on modulating the gut microbiota and improving markers of gastrointestinal permeability and integrity and gastrointestinal discomfort.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Be able to give informed consent.

Be between 50 to 70 years of age (inclusive).

BMI ranging from 25.0 and 35.0 kg/m²

Willing to maintain current level of physical activity and diet during the participation in the study.

Disqualifiers

Has a history of drug and/or alcohol abuse.

Has food allergies, or other issues with foods, that would preclude intake of the study products.

Smoking, chewable tobacco and/or vaping and/or use of other nicotine products.

diagnosis of GI disease (e.g. gastric or duodenal ulcers, inflammatory bowel disease, colon cancer) or irritable bowel syndrome (IBS)

Trial design

Design model

Parallel

Treatments tested in this trial

  • Synbiotic

    Dietary supplement

    Synbiotic \- Given daily for 56 days

  • Placebo

    Dietary supplement

    Placebo \- Given daily for 56 days

Treatment groups

90 Participants
are divided into 2 treatment groups
Group A: SynbioticActive comparator 1 intervention
Group B: PlaceboPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Bifidobacterium abundance

Change in total relative abundance of Bifidobacterium from baseline to 8 weeks assessed from fecal samples. Abundance is calculated based on shotgun metagenomic sequencing.

Time frame
From baseline to end of intervention at 8 weeks

Secondary outcomes

1

Stool frequency

Change in number of daily bowel movements from 2 weeks average prior to baseline to 2 weeks average prior to end of intervention. An increase is desirable.

Time frame
From baseline to end of intervention at 8 weeks
2

Fecal acetate

Change in fecal acetate as measured by targeted metabolomics (GC-MSMS) from baseline to 8 weeks.

Time frame
From baseline to end of intervention at 8 weeks.
3

Fecal propionate

Change in fecal propionate as measured by targeted metabolomics (GC-MSMS) from baseline to 8 weeks.

Time frame
From baseline to end of intervention at 8 weeks.
4

Fecal butyrate

Change in fecal butyrate as measured by targeted metabolomics (GC-MSMS) from baseline to 8 weeks.

Time frame
From baseline to end of intervention at 8 weeks

Other outcomes

1

Recovery of probiotic strains

Recovery and colonization of strains by strain specific qPCR of fecal samples

Time frame
Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up
2

Total relative abundance of Bifidobacterium

Change in total relative abundance of Bifidobacterium after 2 weeks of follow-up (no intervention) compared to effect after 3 weeks and 8 weeks of intervention.

Time frame
Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up.
3

Microbiome composition and taxonomic profiles

Changes in gut microbiome composition and taxonomic profiling analyzed by shotgun metagenomic sequencing of fecal samples

Time frame
Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up
4

Microbiome functional profiling

Change in gut microbiome functional profiling analyzed by shotgun metagenomic sequencing of fecal samples

Time frame
Basline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up

Sponsors and contacts

Click on the lead sponsor to view all of their trials.